NO20091211L - Farmasoytiske clonazepamformuleringer og fremgangsmate for disse - Google Patents

Farmasoytiske clonazepamformuleringer og fremgangsmate for disse

Info

Publication number: NO20091211L
Authority: NO; Norway
Prior art keywords: solvent; benzodiazepine; present; pharmaceutical; relates
Prior art date: 2006-08-28

Application number

NO20091211A

Other languages

English (en)

Norwegian (no)

Inventor

Gene Jamieson

Michael Des Jardin

Clark Allphin

Sigridur Olafsdottir

Original Assignee

Jazz Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-28

Filing date

2009-03-23

Publication date

2009-05-27

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38819711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20091211(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-03-23 Application filed by Jazz Pharmaceuticals Inc filed Critical Jazz Pharmaceuticals Inc

2009-05-27 Publication of NO20091211L publication Critical patent/NO20091211L/no

Links

239000000203 mixture Substances 0.000 title abstract 4
238000009472 formulation Methods 0.000 title abstract 2
DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 title 1
229960003120 clonazepam Drugs 0.000 title 1
238000000034 method Methods 0.000 title 1
239000002904 solvent Substances 0.000 abstract 4
SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract 3
229940049706 benzodiazepine Drugs 0.000 abstract 3
208000019901 Anxiety disease Diseases 0.000 abstract 1
206010010904 Convulsion Diseases 0.000 abstract 1
208000007101 Muscle Cramp Diseases 0.000 abstract 1
206010033664 Panic attack Diseases 0.000 abstract 1
206010071350 Seizure cluster Diseases 0.000 abstract 1
208000005392 Spasm Diseases 0.000 abstract 1
230000036506 anxiety Effects 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
210000004400 mucous membrane Anatomy 0.000 abstract 1
208000019906 panic disease Diseases 0.000 abstract 1
230000000149 penetrating effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Otolaryngology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Anesthesiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

NO20091211A 2006-08-28 2009-03-23 Farmasoytiske clonazepamformuleringer og fremgangsmate for disse NO20091211L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US84056806P	2006-08-28	2006-08-28
PCT/US2007/018877 WO2008027357A2 (en)	2006-08-28	2007-08-27	Pharmaceutical compositions of clonazepam and methods of use thereof

Publications (1)

Publication Number	Publication Date
NO20091211L true NO20091211L (no)	2009-05-27

Family

ID=38819711

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20091211A NO20091211L (no)	2006-08-28	2009-03-23	Farmasoytiske clonazepamformuleringer og fremgangsmate for disse

Country Status (17)

Country	Link
US (2)	US8716279B2 (pt)
EP (2)	EP2068933A2 (pt)
JP (2)	JP2010502614A (pt)
KR (1)	KR20090043603A (pt)
CN (1)	CN101528261B (pt)
AR (1)	AR062556A1 (pt)
AU (1)	AU2007290589B2 (pt)
BR (1)	BRPI0714907A2 (pt)
CA (1)	CA2662197A1 (pt)
IL (1)	IL197275A0 (pt)
MX (1)	MX2009002310A (pt)
NO (1)	NO20091211L (pt)
NZ (2)	NZ595388A (pt)
PE (1)	PE20081361A1 (pt)
TW (1)	TW200824693A (pt)
UY (1)	UY30561A1 (pt)
WO (2)	WO2008027357A2 (pt)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11400065B2 (en)	2019-03-01	2022-08-02	Flamel Ireland Limited	Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11504347B1 (en)	2016-07-22	2022-11-22	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en)	2016-07-22	2023-03-14	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en)	2016-07-22	2023-03-14	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11779557B1 (en)	2022-02-07	2023-10-10	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en)	2016-07-22	2023-12-12	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en)	2016-07-22	2024-05-21	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en)	2016-07-22	2025-01-07	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12295926B1 (en)	2022-02-07	2025-05-13	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en)	2016-07-22	2025-11-25	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200824693A (en)	2006-08-28	2008-06-16	Jazz Pharmaceuticals Inc	Pharmaceutical compositions of clonazepam and methods of use thereof
CN101678112B (zh) *	2007-01-19	2016-08-31	哈南亚有限公司	用于递送治疗剂的方法和组合物
US20080275030A1 (en) *	2007-01-19	2008-11-06	Sveinbjorn Gizurarson	Methods and Compositions for the Delivery of a Therapeutic Agent
TW200922635A (en)	2007-08-31	2009-06-01	Archimedes Dev Ltd	Non-aqueous pharmaceutical compositions
GB0716907D0 (en) *	2007-08-31	2007-10-10	Archimedes Dev Ltd	Pharmaceutical powder compositions
CA2756690C (en)	2008-03-28	2016-08-16	Hale Biopharma Ventures, Llc	Administration of benzodiazepine compositions
KR101517415B1 (ko) *	2008-05-14	2015-05-07	에스케이바이오팜 주식회사	난용성 항경련제를 함유하는 경비 항경련성 약학 조성물
WO2010126963A1 (en) *	2009-04-28	2010-11-04	Optmed, Inc.	Compositions and methods for treating and preventing overactive bladder and conditions associated therewith
WO2010126970A1 (en) *	2009-04-28	2010-11-04	Optmed, Inc.	Methods for treating and preventing erectile dysfunction
GB2481407B (en) *	2010-06-22	2012-05-23	Special Products Ltd	A rapid onset liquid midazolam composition for buccal administration
AU2012236334B2 (en) *	2011-03-31	2017-02-16	Sk Biopharmaceuticals Co., Ltd.	Intranasal benzodiazepine pharmaceutical compositions
EP4085899A1 (en)	2011-06-14	2022-11-09	Neurelis, Inc.	Administration of benzodiazepine
EP2787970B1 (en) *	2011-12-11	2018-04-11	Recro Pharma, Inc.	Intranasal dexmedetomidine compositions and methods of use thereof
US9125805B2 (en) *	2012-06-27	2015-09-08	Xeris Pharmaceuticals, Inc.	Stable formulations for parenteral injection of small molecule drugs
US8999393B1 (en) *	2013-01-09	2015-04-07	Edgemont Pharmaceuticals Llc	Sustained release formulations of lorazepam
US20160000702A1 (en) *	2013-02-22	2016-01-07	Eastgate Pharmaceuticals Inc.	Pharmaceutical composition for enhanced transmucosal adminstration of benzodiazepines
KR101635635B1 (ko) *	2014-12-04	2016-07-01	주식회사 엘지생활건강	디팔미토일 하이드록시프롤린과 갈릭산 에스터 유도체를 함유하는 화장료 조성물
CA2987242C (en)	2015-05-25	2023-10-10	Isotherapeutics Group, Llc	Dotmp kit formulations for radioisotopes
AU2017370747A1 (en) *	2016-12-09	2019-06-27	Alexza Pharmaceuticals, Inc.	Method of treating epilepsy
CN111886007A (zh) *	2017-11-17	2020-11-03	纽兰娜制药股份有限公司	托哌酮的施用方法
EP3735223A4 (en)	2018-01-05	2021-10-13	Impel Neuropharma Inc.	INTRANASAL ADMINISTRATION OF OLANZAPINE BY A PRECISION OLFACTORY DEVICE
US10896106B2 (en) *	2018-05-10	2021-01-19	Teradyne, Inc.	Bus synchronization system that aggregates status
US20200338090A1 (en) *	2019-04-29	2020-10-29	Marsh and Wang Medical Systems, LLC	Seizure control compositions and methods of using same
CN110420190B (zh) *	2019-08-29	2021-07-09	湖南洞庭药业股份有限公司	氯硝西泮片及其制备方法
AU2022290861A1 (en) *	2021-06-10	2023-12-07	Neurelis, Inc.	Methods and compositions for treating seizure disorders in pediatric patients
CN115707451A (zh) *	2021-08-19	2023-02-21	北京万全德众医药生物技术有限公司	氯硝西泮口服溶液
CN114656410A (zh) *	2022-03-02	2022-06-24	济南同路医药科技发展有限公司	一种氯硝西泮杂质及其制备方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5266466A (en) *	1987-01-14	1993-11-30	President And Fellows Of Harvard College	Method of using T7 DNA polymerase to label the 3' end of a DNA molecule
SE8800080L (sv)	1988-01-13	1989-07-14	Kabivitrum Ab	Laekemedelskomposition
US4950664A (en) *	1988-09-16	1990-08-21	Rugby-Darby Group Companies, Inc.	Nasal administration of benzodiazepine hypnotics
FR2656303B1 (fr) *	1989-12-26	1994-06-10	Parke Davis	Solution buvable d'un derive des benzodiazepines et son application pharmacologique.
WO1991016929A1 (en)	1990-05-10	1991-11-14	Novo Nordisk A/S	A pharmaceutical preparation containing n-glycofurols and n-ethylene glycols
DE4021263C2 (de) *	1990-07-04	1996-04-11	Pfeiffer Erich Gmbh & Co Kg	Austragvorrichtung für Medien
FR2692174B1 (fr) *	1992-06-16	1994-08-19	Valois	Dispositif à gaz comprimé pour projeter sous forme finement divisée une dose unique d'une substance fluide.
DK17093D0 (da) *	1993-02-15	1993-02-15	Lyfjathroun H F	Farmaceutisk praeparat til topisk administrering af antigener og/eller vacciner til pattedyr via slimhinder
AU2345695A (en)	1994-04-28	1995-11-29	F. Hoffmann-La Roche Ag	Pharmaceutical composition for transdermal delivery
GB9409778D0 (en) *	1994-05-16	1994-07-06	Dumex Ltd As	Compositions
US20050163719A1 (en) *	1997-10-01	2005-07-28	Dugger Harry A.Iii	Buccal, polar and non-polar spray containing diazepam
DE19756442A1 (de) *	1997-12-18	1999-06-24	Pfeiffer Erich Gmbh & Co Kg	Spender für Medien
US6699849B1 (en) *	1998-02-23	2004-03-02	Cyclops, Ehf.	Cyclodextrin complexes of benzodiazepines
SE9803240D0 (sv)	1998-09-24	1998-09-24	Diabact Ab	A pharmaceutical composition having a rapid action
GB9826192D0 (en) *	1998-12-01	1999-01-20	Controlled Theraputics Scotlan	Oral transmucosal delivery
ES2304969T3 (es) *	1999-07-26	2008-11-01	Sk Holdings Co., Ltd.	Composiciones anticonvulsivas transnasales.
DE19938798A1 (de) *	1999-08-16	2001-03-01	Pfeiffer Erich Gmbh & Co Kg	Spender für Flüssigkeiten oder für zähflüssige oder versprühbare Produkte
DE19940236A1 (de) *	1999-08-25	2001-03-08	Pfeiffer Erich Gmbh & Co Kg	Spender mit manuell betätigbarer Ausbringeinrichtung
US6610271B2 (en) *	2000-05-10	2003-08-26	University Of Kentucky Research Foundation	System and method for intranasal administration of lorazepam
AR030312A1 (es)	2000-08-03	2003-08-20	Antares Pharma Ipl Ag	Composicion novedosa para la administracion transdermica y/o transmucosica de compuestos activos, que asegura adecuados niveles terapeuticos
FR2815611B1 (fr) *	2000-10-23	2003-04-11	Valois Sa	Tete de distribution et distributeur de produit fluide comportant une telle tete de distribution
US20040176359A1 (en) *	2001-02-20	2004-09-09	University Of Kentucky Research Foundation	Intranasal Benzodiazepine compositions
CA2456754A1 (en) *	2001-08-08	2003-02-20	Yuji Iizawa	Benzazepine derivative, process for producing the same, and use
WO2003070280A2 (en)	2002-02-25	2003-08-28	Lyfjathroun Hf	Absorption enhancing agent
US6742677B2 (en) *	2002-04-18	2004-06-01	Valois S.A.S.	Fluid dispenser pump
US7939098B2 (en) *	2002-05-23	2011-05-10	Femina Pharma Incorporated	Compositions and method for transmucosal drug delivery and cryoprotection
ITRM20020357A1 (it) *	2002-07-03	2004-01-05	Foscama Biomed Chim Farma	Composizione liquida per la somministrazione orale di lorazepam.
US6855332B2 (en) *	2002-07-03	2005-02-15	Lyfjathroun Hf.	Absorption promoting agent
CN100581586C (zh)	2003-01-31	2010-01-20	奥雷克索公司	一种快速起效的药物组合物
CN100421649C (zh) *	2003-06-17	2008-10-01	Sk株式会社	含地西泮的经鼻微乳
NZ546106A (en)	2003-10-10	2008-10-31	Antares Pharma Ipl Ag	Transdermal pharmaceutical formulation for minimizing skin residues
WO2006075125A1 (en) *	2005-01-14	2006-07-20	Camurus Ab	GnRH ANALOGUE FORMULATIONS
US20070021411A1 (en) *	2005-05-11	2007-01-25	Cloyd James C	Supersaturated benzodiazepine solutions and their delivery
TW200824693A (en) *	2006-08-28	2008-06-16	Jazz Pharmaceuticals Inc	Pharmaceutical compositions of clonazepam and methods of use thereof
US9319244B2 (en)	2010-12-22	2016-04-19	Usablenet Inc.	Methods for emailing labels as portable data files and devices thereof

2007
- 2007-08-14 TW TW096130010A patent/TW200824693A/zh unknown
- 2007-08-23 PE PE2007001144A patent/PE20081361A1/es not_active Application Discontinuation
- 2007-08-27 KR KR1020097006303A patent/KR20090043603A/ko not_active Ceased
- 2007-08-27 AU AU2007290589A patent/AU2007290589B2/en not_active Ceased
- 2007-08-27 BR BRPI0714907-7A patent/BRPI0714907A2/pt not_active IP Right Cessation
- 2007-08-27 WO PCT/US2007/018877 patent/WO2008027357A2/en not_active Ceased
- 2007-08-27 CN CN2007800399467A patent/CN101528261B/zh not_active Expired - Fee Related
- 2007-08-27 NZ NZ595388A patent/NZ595388A/en not_active IP Right Cessation
- 2007-08-27 NZ NZ575744A patent/NZ575744A/en not_active IP Right Cessation
- 2007-08-27 UY UY30561A patent/UY30561A1/es unknown
- 2007-08-27 JP JP2009526683A patent/JP2010502614A/ja not_active Ceased
- 2007-08-27 CA CA002662197A patent/CA2662197A1/en not_active Abandoned
- 2007-08-27 WO PCT/US2007/018942 patent/WO2008027395A2/en not_active Ceased
- 2007-08-27 EP EP07837400A patent/EP2068933A2/en not_active Withdrawn
- 2007-08-27 JP JP2009526675A patent/JP2010502612A/ja not_active Ceased
- 2007-08-27 MX MX2009002310A patent/MX2009002310A/es not_active Application Discontinuation
- 2007-08-27 US US11/897,002 patent/US8716279B2/en not_active Expired - Fee Related
- 2007-08-27 US US11/897,028 patent/US8609651B2/en not_active Expired - Fee Related
- 2007-08-27 EP EP07811570A patent/EP2056877A2/en not_active Withdrawn
- 2007-08-28 AR ARP070103802A patent/AR062556A1/es not_active Application Discontinuation
2009
- 2009-02-26 IL IL197275A patent/IL197275A0/en unknown
- 2009-03-23 NO NO20091211A patent/NO20091211L/no not_active Application Discontinuation

Cited By (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US12115143B2 (en)	2016-07-22	2024-10-15	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12128021B1 (en)	2016-07-22	2024-10-29	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en)	2016-07-22	2023-03-14	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en)	2016-07-22	2023-03-14	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11766418B2 (en)	2016-07-22	2023-09-26	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en)	2016-07-22	2025-11-25	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11826335B2 (en)	2016-07-22	2023-11-28	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11839597B2 (en)	2016-07-22	2023-12-12	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11896572B2 (en)	2016-07-22	2024-02-13	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en)	2016-07-22	2024-05-21	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12097175B2 (en)	2016-07-22	2024-09-24	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12097176B2 (en)	2016-07-22	2024-09-24	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12109186B2 (en)	2016-07-22	2024-10-08	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115142B2 (en)	2016-07-22	2024-10-15	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115144B2 (en)	2016-07-22	2024-10-15	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12115145B2 (en)	2016-07-22	2024-10-15	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en)	2016-07-22	2022-11-22	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12263150B2 (en)	2016-07-22	2025-04-01	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12138239B2 (en)	2016-07-22	2024-11-12	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12144793B2 (en)	2016-07-22	2024-11-19	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12263151B2 (en)	2016-07-22	2025-04-01	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12257223B2 (en)	2016-07-22	2025-03-25	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en)	2016-07-22	2025-01-07	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186298B2 (en)	2016-07-22	2025-01-07	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12239625B2 (en)	2016-07-22	2025-03-04	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12226389B2 (en)	2016-07-22	2025-02-18	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12226388B2 (en)	2016-07-22	2025-02-18	Flamel Ireland Limited	Modified release gamma- hydroxybutyrate formulations having improved pharmacokinetics
US12226377B2 (en)	2019-03-01	2025-02-18	Flamel Ireland Limited	Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12167991B2 (en)	2019-03-01	2024-12-17	Flamel Ireland Limited	Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12167992B2 (en)	2019-03-01	2024-12-17	Flamel Ireland Limited	Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US11400065B2 (en)	2019-03-01	2022-08-02	Flamel Ireland Limited	Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12303478B2 (en)	2019-03-01	2025-05-20	Flamel Ireland Limited	Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
US12295926B1 (en)	2022-02-07	2025-05-13	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11779557B1 (en)	2022-02-07	2023-10-10	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12551457B1 (en)	2022-02-07	2026-02-17	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Also Published As

Publication number	Publication date
NZ575744A (en)	2011-10-28
WO2008027395A3 (en)	2008-04-17
WO2008027395A2 (en)	2008-03-06
JP2010502614A (ja)	2010-01-28
NZ595388A (en)	2011-12-22
IL197275A0 (en)	2009-12-24
CN101528261A (zh)	2009-09-09
KR20090043603A (ko)	2009-05-06
MX2009002310A (es)	2009-09-21
WO2008027357A9 (en)	2009-04-30
AR062556A1 (es)	2008-11-19
TW200824693A (en)	2008-06-16
BRPI0714907A2 (pt)	2014-08-19
EP2056877A2 (en)	2009-05-13
WO2008027357A2 (en)	2008-03-06
CA2662197A1 (en)	2008-03-06
AU2007290589A1 (en)	2008-03-06
AU2007290589B2 (en)	2012-04-05
UY30561A1 (es)	2008-03-31
US8716279B2 (en)	2014-05-06
US8609651B2 (en)	2013-12-17
US20080070904A1 (en)	2008-03-20
WO2008027357A3 (en)	2008-04-17
US20080076761A1 (en)	2008-03-27
PE20081361A1 (es)	2008-11-06
EP2068933A2 (en)	2009-06-17
JP2010502612A (ja)	2010-01-28
CN101528261B (zh)	2012-07-18

Legal Events

Date	Code	Title	Description
2015-03-23	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20091211L (no)	2009-05-27	Farmasoytiske clonazepamformuleringer og fremgangsmate for disse
MA33044B1 (fr)	2012-02-01	Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient
NO20090157L (no)	2009-01-12	Tienpyrimidiner anvendelige som modulatorer av ionekanaler
NO20055129L (no)	2006-01-23	Fenylsubstituerte karboksylsyrer
PL360495A1 (en)	2004-09-06	Arylmethylamine derivatives for use as tryptase inhibitors
NO20064976L (no)	2006-10-31	Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
TR200201004T2 (tr)	2002-11-21	Monoamin reuptake önleyicileri olarak biaril eter türevleri
BRPI0515931A (pt)	2008-08-12	compostos, processo para a sua preparação, composições farmacêuticas que os compreendem, método para o tratamento e/ou profilaxia de enfermidades e utilização desses compostos
EA200802020A1 (ru)	2009-04-28	Тетрагидропиримидоазепины и их применение в качестве модуляторов trpv 1
NO20084826L (no)	2008-12-12	Ny administrasjonsform av racecadotril
NO20050851L (no)	2005-03-29	Kaspase-inhibitorer og anvendelser derav
EA200201276A1 (ru)	2003-06-26	Производные арилметиламина для использования в качестве ингибиторов триптазы
BR0313718A (pt)	2005-07-12	Composto, processo para a preparação do mesmo, composição farmacêutica, métodos para tratar um indivìduo humano ou animal sofrendo de uma condição que é mediada por cox-2 e para tratar um indivìduo humano ou animal sofrendo de um distúrbio inflamatório, e, uso de um composto
MX2008013017A (es)	2008-11-27	Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
AR045061A1 (es)	2005-10-12	Formulacion farmaceutica y metodo para tratar trastornos gastrointestinales causados por acido
RU2010135252A (ru)	2012-05-10	Применение маслиновой кислоты для лечения заболеваний и их симптомов посредством ингибирования сох-2
EA200501865A1 (ru)	2006-08-25	Аналоги тиовольфраматов и их применение
UA100326C2 (uk)	2012-12-10	Мазь для місцевого лікування геморою
NO20030155L (no)	2003-03-13	Farmasöytiske sammensetninger og fremgangsmåter for anvendelse derav
HK1131069A (en)	2010-01-15	Pharmaceutical compositions of clonazepam and methods of use thereof
Chen et al.	2025	Synergistic effects of heterophyllin B with nintedanib against experimental pulmonary fibrosis in mice
HK1129207A (en)	2009-11-20	Pharmaceutical compositions of benzodiazepines and methods of use thereof
BRPI0511714A (pt)	2008-01-08	composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, método para tratar uma doença em um animal
WO2007146375A3 (en)	2008-04-03	Highly soluble pyrimido-dione-quinoline compounds and their use in the treatment of cancer
PL379512A1 (pl)	2007-10-29	Nowe metody i ich zastosowanie